Well this was a bit of a surprise, but considering the market outside of C-19 ARDS, there’s a larger prize in the horizon!
Also, @Duku I wouldn’t call CHF a fail because of the 60% reduction in mortality that is really, a key secondary endpoint.
That sort of data from the trial is very compelling!
Ive not sold anything yet, in it for the long run!
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-131
-
- There are more pages in this discussion • 945 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |